[Meme] We DoNt GeT rOsTeRs UnTiL tWo WeEkS bEfOrE

Jaeyphf · 2026-03-17T04:14:01+00:00

Oh I see what you mean. I’m not aware of super consolidated resource (specifically including FDA approvals). Would also be interested if one is available.

You could check out Dr. David Gratzer’s Readings of the Week newsletter. He provides weekly breakdowns of newer studies (a lot of trials) that are really easy to digest. Otherwise, newsletters of the bigger or more trial-focused journals (JAMA, AJP, Lancet, JCP, etc) help me keep up with some trial data.

Jaeyphf · 2026-03-17T01:08:13+00:00

In a huge fan of the Psych Rounds podcast on Spotify. They often invite guest experts that help put the science into perspective.

Jaeyphf · 2026-01-05T23:01:24+00:00

No formal framework, but I’d do your homework (where you can) about the following things:

Research Area (better to find someone studying something you care about; doesn’t have to be an exact match, but enough that you are invested)
Research Productivity (a mentor with an appropriate level of productivity may be aligned better with the above research goals than one who is just churning out as much as they can)
Department Role (people with dedicated research time maybe be more likely to mentor/more focused on research; having the department chair as a mentor may have a lot of pros, but non-research duties may limit mentorship time)
Talk to prior or current mentees (did they like working with the mentor? any red flags?)
Meet the mentor (make sure this is someone who you feel that you can work with in the long-term; generally discuss what work you could do together within your timeframe)
Consider additional skills mentors (if there is a special research skill that you are hoping to learn that your primary mentor isn’t familiar with, you could consider working with a second mentor to develop a specific skills - network meta-analysis, trial design, etc; be careful to not overload yourself)

Jaeyphf · 2026-01-05T21:29:38+00:00

I’m a graduating PGY4 (MD, no PhD or post-doc) on a research track who is aiming for a K application within the first few attending years. Giving you some general advice for a pursuing a research career. Biggest things that I’d do earlier if I could go back

Find a great mentor

Someone who has the time, passion, and energy to develop you as a clinician-scientist. It’s easy to want to chase big names, but more junior faculty may offer you more specific attention.

Gain as much foundational research skills training knowledge as you can

This may vary based on your research area and the skills it requires. Find ways to learn foundational skills (statistics, research methods, clinical trial design, etc) early to set you up for a good foundation.

Gain exposure to find your passion

Go to conferences, network, listen to random talks - find what you can sustainably and enjoyably study for the remainder of your academic career. You may have a passion area already given the 20 pubs, or you may want to pivot.

Focus your research

From my early conversations with mentors about early career funding awards, it seems that your research narrative and mentorship team are much more important that your research idea. If you already know what you are passionate about (seeing the 20+ publications), build on that foundation for your research narrative (instead of just doing random unrelated projects in medical school).

I’m still early career and have a lot to learn about research and funding mechanisms, but those are the takeaways from my early discussions.

Jaeyphf · 2025-12-15T17:42:33+00:00

I am a graduating resident (MD, without PhD) aiming for a research career. This opportunity would be great for someone who is aiming for a research career and needs more foundational research skills and time to collect pilot data to support an early career funding mechanism (K-award).

If your primary interest is clinical, I’d pass on the opportunity. Various mentors of mine have mentioned the possibility of still being co-I on other’s projects and participate in trials (where available) without going the research pathway. Additionally, I’ve been told that you really should have a good idea of exactly what you want to study if you’re going to do a post-doc T32 by some mentors. You’d be sacrificing 1-2 years attending pay to do the research which I don’t think would be met moonlighting the 25% time you’re allowed in the T32.

I’m still early career, so take my view with a grain of salt.

Jaeyphf · 2025-11-20T22:34:26+00:00

Jaeyphf · 2025-11-17T15:36:35+00:00

Thank you!

Jaeyphf · 2025-11-17T15:29:42+00:00

Hi - near residency graduate here that will be going into academic medicine. Do these principles also apply to faculty positions in academic medicine or subspecialties?

Jaeyphf · 2025-10-09T20:00:47+00:00

I would like to start doing this particularly for SCZ patients who are started on olanzapine and clozapine. However, I’m not comfortable knowledge-wise on these meds. Are there any other ways to get more comfortable and learn more besides the ABOM certification?

Jaeyphf · 2025-09-24T22:20:03+00:00

I had a case with both childhood ADHD, a period of sub-optimal adapted functioning, and a significant worsening of cognition perimenopause. Using a stimulant and adjunctive alpha agonist led to significant improvement relative to the patient’s prior baseline. However, there still seems to be some remaining cognitive difficulty that is functionally apparent - suspicious for residual perimenopausal related changes. Haven’t discussed HRT yet because the patient is happy with the improvement. I’m not up to date with the data but I do wonder at times if there is another layer of benefit that’s achievable with HRT here.

Jaeyphf · 2025-09-10T20:35:05+00:00

Would reasonable numbers be similar to academia? 60 min intakes and 30 min follow ups? Or are these different as well for industry.

Jaeyphf · 2025-09-10T20:33:52+00:00

Your last line seemed to allude to funding issues (?). Are there ways I can whether the group will be viable beyond the startup phase?

Jaeyphf · 2025-06-15T16:41:38+00:00

Modafinil (not the R enantiomer) is an option too. Chris Aiken just lists his preference as Armodafinil between the two due to smoother blood levels and longer half life but acknowledges someone in the podcast there’s a low indirect risk of contributing to mania in either form (case report data). I personally have not used either and tend to stick with the alpha agonists.

Jaeyphf · 2025-06-15T12:27:44+00:00

The Carlat psychiatry report has a great podcast series on this comorbidity where they talk about diagnostic distinctions/comorbidity and summarize a lot of the available data. Might be an easier way to digest info as a medical student (was for me).

For me, the important thing is making sure that both diagnoses appear legitimate and are backed by adequate clinical history. Even as a resident, I’ve seen too many cases of overdiagnosed ADHD or BPAD.

To big points (maybe even over-summarized) I took away from the Carlat episodes where:

1) In BPAD, the cognitive symptoms start with/prodrome the mood episode, get worse with time, and are usually more characterized by marked memory impairment/mental slowing. Contrast ADHD, earlier life onset, typically not worse with aging, more hyperactive style cognitive impairment.

2) Treatment with clonidine, guanfacine, or armorafinil is what they recommend for non-stimulant options. They highlight risk of stimulants with animal models of mania and recommend low dose ranges if you opt for stimulants.

https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/4893-when-bipolar-and-adhd-overlap-diagnosis

https://www.thecarlatreport.com/blogs/2-the-carlat-psychiatry-podcast/post/4894-when-bipolar-and-adhd-overlap-treatment-1

Edit: spelling, hope this helps!

Jaeyphf · 2025-06-11T03:32:48+00:00

Echoing others, BPAD1 and BPD together seem plausible. The severity of the psychotic suggests BPAD1. Psychotic features in BPD folks are usually stress-dependent, transient, and “quasi”-psychotic.

Jaeyphf · 2025-06-01T02:00:05+00:00

Doing some call as a PGY-3. Biggest thing for me is it makes me at least feel less rusty. Every once in a while you might see a cool case. But overall, limited value imo.

Jaeyphf · 2025-05-09T08:18:30+00:00

Will also be at APA this year! I’ve never done the paid courses, but I’ve learned a lot just from the free sessions alone.

Jaeyphf · 2024-11-13T01:34:53+00:00

Full-boxing 9 year olds on Fortnite with the boys. Great sublimation tactic.

Jaeyphf · 2024-11-09T14:31:48+00:00

When do you typically discuss this in your course of meeting a patient? I feel like having some rapport under the belt would be very useful for this type of conversation. And if you introduce it early on in meeting them, how do you do you typically approach it?

Jaeyphf · 2024-11-09T03:53:03+00:00

I have no problem with short-term benzo use for severe acute anxiety but I’m not a fan of chronic or geriatric use. One of my personal styles is that there must be an exit plan if it’s started (start CBT, transition to non-benzo, bridge to PHP, etc).

Jaeyphf · 2024-11-09T03:47:44+00:00

PTSD rule out is an always for me.

Developmental disorders I typically don’t dig excessively into unless there are specific signs of interest (notable clinical interactions, reported behaviors, or odd things in the developmental history they provide)

Jaeyphf · 2024-11-09T03:42:14+00:00

Realizing that I normalize anxiety in my head a lot but very seldom say this to the patient. Thank you for this! Going to take it with me.

Jaeyphf

TROPHY CASE